---
document_datetime: 2025-12-25 08:00:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-koanaa.html
document_name: rivaroxaban-koanaa.html
version: success
processing_time: 0.1013315
conversion_datetime: 2025-12-27 23:04:14.224911
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rivaroxaban Koanaa

[RSS](/en/individual-human-medicine.xml/266964)

##### Authorised

This medicine is authorised for use in the European Union

rivaroxaban Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rivaroxaban Koanaa](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Rivaroxaban Koanaa is an anticoagulant medicine (a medicine that prevents blood clotting) used:

- to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (a clot in a blood vessel supplying the lungs), and to prevent DVT and pulmonary embolism from recurring in adults;
- to prevent venous thromboembolism (VTE, the formation of blood clots in the veins) in adults who are undergoing surgery to replace a hip or knee;
- to treat VTE and prevent VTE from recurring in children and adolescents aged less than 18 years;
- to prevent stroke (caused by a blood clot in the brain) and systemic embolism (a blood clot in another organ) in adults with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart).

Rivaroxaban Koanaa contains the active substance rivaroxaban and is a 'generic medicine'. This means that Rivaroxaban Koanaa contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Rivaroxaban Koanaa is Xarelto. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Rivaroxaban Koanaa used?

Rivaroxaban Koanaa is available as a film to be placed on the tongue, where it will disperse rapidly. The dose and duration of treatment with Rivaroxaban Koanaa depend on what it is being used for and the patient's risk of bleeding. For children, the dose and duration of treatment also depend on the patient's age and weight.

The medicine can only be obtained with a prescription. For more information about using Rivaroxaban Koanaa, see the package leaflet or contact your doctor or pharmacist.

## How does Rivaroxaban Koanaa work?

The active substance in Rivaroxaban Koanaa, rivaroxaban, is a factor Xa inhibitor. This means that it blocks factor Xa, an enzyme that is involved in the production of thrombin. Thrombin is central to the process of blood clotting. By blocking factor Xa, the levels of thrombin decrease, which reduces the risk of blood clots forming in the veins and arteries, and also treats existing clots.

## How has Rivaroxaban Koanaa been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Xarelto, and do not need to be repeated for Rivaroxaban Koanaa.

As for every medicine, the company provided studies on the quality of Rivaroxaban Koanaa. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Rivaroxaban Koanaa?

Because Rivaroxaban Koanaa is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Rivaroxaban Koanaa authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Rivaroxaban Koanaa has been shown to have comparable quality and to be bioequivalent to Xarelto. Therefore, the Agency's view was that, as for Xarelto, the benefits of Rivaroxaban Koanaa outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Rivaroxaban Koanaa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rivaroxaban Koanaa have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Xarelto also apply to Rivaroxaban Koanaa where appropriate.

As for all medicines, data on the use of Rivaroxaban Koanaa are continuously monitored. Suspected side effects reported with Rivaroxaban Koanaa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Rivaroxaban Koanaa

Rivaroxaban Koanaa received a marketing authorisation valid throughout the EU on 21 November 2025.

Rivaroxaban Koanaa : EPAR - Medicine overview

Reference Number: EMA/319706/2025

English (EN) (167.38 KB - PDF)

**First published:** 17/12/2025

[View](/en/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-326)

български (BG) (189.54 KB - PDF)

**First published:**

17/12/2025

[View](/bg/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_bg.pdf)

español (ES) (167.56 KB - PDF)

**First published:**

17/12/2025

[View](/es/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_es.pdf)

čeština (CS) (187.27 KB - PDF)

**First published:**

17/12/2025

[View](/cs/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_cs.pdf)

dansk (DA) (166.64 KB - PDF)

**First published:**

17/12/2025

[View](/da/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_da.pdf)

Deutsch (DE) (170.41 KB - PDF)

**First published:**

17/12/2025

[View](/de/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_de.pdf)

eesti keel (ET) (164.87 KB - PDF)

**First published:**

17/12/2025

[View](/et/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (179.34 KB - PDF)

**First published:**

17/12/2025

[View](/el/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_el.pdf)

français (FR) (169.73 KB - PDF)

**First published:**

17/12/2025

[View](/fr/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (187.71 KB - PDF)

**First published:**

17/12/2025

[View](/hr/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_hr.pdf)

italiano (IT) (166.72 KB - PDF)

**First published:**

17/12/2025

[View](/it/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (203.77 KB - PDF)

**First published:**

17/12/2025

[View](/lv/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (187.99 KB - PDF)

**First published:**

17/12/2025

[View](/lt/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_lt.pdf)

magyar (HU) (188.76 KB - PDF)

**First published:**

17/12/2025

[View](/hu/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_hu.pdf)

Malti (MT) (188.88 KB - PDF)

**First published:**

17/12/2025

[View](/mt/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (158.31 KB - PDF)

**First published:**

17/12/2025

[View](/nl/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_nl.pdf)

polski (PL) (192.11 KB - PDF)

**First published:**

17/12/2025

[View](/pl/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_pl.pdf)

português (PT) (168.26 KB - PDF)

**First published:**

17/12/2025

[View](/pt/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_pt.pdf)

română (RO) (187.19 KB - PDF)

**First published:**

17/12/2025

[View](/ro/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (187.57 KB - PDF)

**First published:**

17/12/2025

[View](/sk/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (185.22 KB - PDF)

**First published:**

17/12/2025

[View](/sl/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_sl.pdf)

Suomi (FI) (165.08 KB - PDF)

**First published:**

17/12/2025

[View](/fi/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_fi.pdf)

svenska (SV) (166.12 KB - PDF)

**First published:**

17/12/2025

[View](/sv/documents/overview/rivaroxaban-koanaa-epar-medicine-overview_sv.pdf)

Rivaroxaban Koanaa : EPAR - Risk management plan

English (EN) (505.33 KB - PDF)

**First published:** 17/12/2025

[View](/en/documents/rmp/rivaroxaban-koanaa-epar-risk-management-plan_en.pdf)

## Product information

Rivaroxaban Koanaa : EPAR - Product information

English (EN) (1.29 MB - PDF)

**First published:** 17/12/2025

[View](/en/documents/product-information/rivaroxaban-koanaa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-798)

български (BG) (1.52 MB - PDF)

**First published:**

17/12/2025

[View](/bg/documents/product-information/rivaroxaban-koanaa-epar-product-information_bg.pdf)

español (ES) (1.3 MB - PDF)

**First published:**

17/12/2025

[View](/es/documents/product-information/rivaroxaban-koanaa-epar-product-information_es.pdf)

čeština (CS) (1.43 MB - PDF)

**First published:**

17/12/2025

[View](/cs/documents/product-information/rivaroxaban-koanaa-epar-product-information_cs.pdf)

dansk (DA) (1.17 MB - PDF)

**First published:**

17/12/2025

[View](/da/documents/product-information/rivaroxaban-koanaa-epar-product-information_da.pdf)

Deutsch (DE) (1.37 MB - PDF)

**First published:**

17/12/2025

[View](/de/documents/product-information/rivaroxaban-koanaa-epar-product-information_de.pdf)

eesti keel (ET) (1.27 MB - PDF)

**First published:**

17/12/2025

[View](/et/documents/product-information/rivaroxaban-koanaa-epar-product-information_et.pdf)

ελληνικά (EL) (1.53 MB - PDF)

**First published:**

17/12/2025

[View](/el/documents/product-information/rivaroxaban-koanaa-epar-product-information_el.pdf)

français (FR) (1.35 MB - PDF)

**First published:**

17/12/2025

[View](/fr/documents/product-information/rivaroxaban-koanaa-epar-product-information_fr.pdf)

hrvatski (HR) (1.42 MB - PDF)

**First published:**

17/12/2025

[View](/hr/documents/product-information/rivaroxaban-koanaa-epar-product-information_hr.pdf)

íslenska (IS) (1.34 MB - PDF)

**First published:**

17/12/2025

[View](/is/documents/product-information/rivaroxaban-koanaa-epar-product-information_is.pdf)

italiano (IT) (1.34 MB - PDF)

**First published:**

17/12/2025

[View](/it/documents/product-information/rivaroxaban-koanaa-epar-product-information_it.pdf)

latviešu valoda (LV) (1.45 MB - PDF)

**First published:**

17/12/2025

[View](/lv/documents/product-information/rivaroxaban-koanaa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.43 MB - PDF)

**First published:**

17/12/2025

[View](/lt/documents/product-information/rivaroxaban-koanaa-epar-product-information_lt.pdf)

magyar (HU) (1.46 MB - PDF)

**First published:**

17/12/2025

[View](/hu/documents/product-information/rivaroxaban-koanaa-epar-product-information_hu.pdf)

Malti (MT) (1.48 MB - PDF)

**First published:**

17/12/2025

[View](/mt/documents/product-information/rivaroxaban-koanaa-epar-product-information_mt.pdf)

Nederlands (NL) (1.24 MB - PDF)

**First published:**

17/12/2025

[View](/nl/documents/product-information/rivaroxaban-koanaa-epar-product-information_nl.pdf)

norsk (NO) (1.3 MB - PDF)

**First published:**

17/12/2025

[View](/no/documents/product-information/rivaroxaban-koanaa-epar-product-information_no.pdf)

polski (PL) (1.42 MB - PDF)

**First published:**

17/12/2025

[View](/pl/documents/product-information/rivaroxaban-koanaa-epar-product-information_pl.pdf)

português (PT) (1.29 MB - PDF)

**First published:**

17/12/2025

[View](/pt/documents/product-information/rivaroxaban-koanaa-epar-product-information_pt.pdf)

română (RO) (1.46 MB - PDF)

**First published:**

17/12/2025

[View](/ro/documents/product-information/rivaroxaban-koanaa-epar-product-information_ro.pdf)

slovenčina (SK) (1.39 MB - PDF)

**First published:**

17/12/2025

[View](/sk/documents/product-information/rivaroxaban-koanaa-epar-product-information_sk.pdf)

slovenščina (SL) (1.35 MB - PDF)

**First published:**

17/12/2025

[View](/sl/documents/product-information/rivaroxaban-koanaa-epar-product-information_sl.pdf)

Suomi (FI) (1.34 MB - PDF)

**First published:**

17/12/2025

[View](/fi/documents/product-information/rivaroxaban-koanaa-epar-product-information_fi.pdf)

svenska (SV) (1.18 MB - PDF)

**First published:**

17/12/2025

[View](/sv/documents/product-information/rivaroxaban-koanaa-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rivaroxaban Koanaa : EPAR - All authorised presentations

English (EN) (45.81 KB - PDF)

**First published:** 17/12/2025

[View](/en/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-73)

български (BG) (54.44 KB - PDF)

**First published:**

17/12/2025

[View](/bg/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_bg.pdf)

español (ES) (44.67 KB - PDF)

**First published:**

17/12/2025

[View](/es/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (55.79 KB - PDF)

**First published:**

17/12/2025

[View](/cs/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.4 KB - PDF)

**First published:**

17/12/2025

[View](/da/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (80.86 KB - PDF)

**First published:**

17/12/2025

[View](/de/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.95 KB - PDF)

**First published:**

17/12/2025

[View](/et/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (105.9 KB - PDF)

**First published:**

17/12/2025

[View](/el/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_el.pdf)

français (FR) (46.44 KB - PDF)

**First published:**

17/12/2025

[View](/fr/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (64.68 KB - PDF)

**First published:**

17/12/2025

[View](/hr/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (45.87 KB - PDF)

**First published:**

17/12/2025

[View](/is/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.52 KB - PDF)

**First published:**

17/12/2025

[View](/it/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (66.93 KB - PDF)

**First published:**

17/12/2025

[View](/lv/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (67.84 KB - PDF)

**First published:**

17/12/2025

[View](/lt/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (64.34 KB - PDF)

**First published:**

17/12/2025

[View](/hu/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (65.15 KB - PDF)

**First published:**

17/12/2025

[View](/mt/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.22 KB - PDF)

**First published:**

17/12/2025

[View](/nl/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.54 KB - PDF)

**First published:**

17/12/2025

[View](/no/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.94 KB - PDF)

**First published:**

17/12/2025

[View](/pl/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.23 KB - PDF)

**First published:**

17/12/2025

[View](/pt/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_pt.pdf)

română (RO) (62.84 KB - PDF)

**First published:**

17/12/2025

[View](/ro/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (63.5 KB - PDF)

**First published:**

17/12/2025

[View](/sk/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (62.14 KB - PDF)

**First published:**

17/12/2025

[View](/sl/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.44 KB - PDF)

**First published:**

17/12/2025

[View](/fi/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (44.85 KB - PDF)

**First published:**

17/12/2025

[View](/sv/documents/all-authorised-presentations/rivaroxaban-koanaa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rivaroxaban Koanaa Active substance rivaroxaban International non-proprietary name (INN) or common name rivaroxaban Therapeutic area (MeSH)

- Venous Thromboembolism
- Pulmonary Embolism
- Venous Thrombosis
- Stroke
- Embolism

Anatomical therapeutic chemical (ATC) code B01AF01

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)

## Authorisation details

EMA product number EMEA/H/C/006643

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Koanaa Healthcare GmbH

Fehrgasse 7

Opinion adopted 18/09/2025 Marketing authorisation issued 21/11/2025

## Assessment history

## Initial marketing authorisation documents

Rivaroxaban Koanaa : EPAR - Public assessment report

Adopted

Reference Number: EMA/335639/2025

English (EN) (642.56 KB - PDF)

**First published:** 17/12/2025

[View](/en/documents/assessment-report/rivaroxaban-koanaa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rivaroxaban Koanaa

Adopted

Reference Number: EMA/CHMP/297836/2025

English (EN) (166.03 KB - PDF)

**First published:** 19/09/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rivaroxaban-koanaa_en.pdf)

#### News on Rivaroxaban Koanaa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-september-2025) 19/09/2025

**This page was last updated on** 17/12/2025

## Share this page

[Back to top](#main-content)